From the INSERM UMR-S 1166 (A.-S.P.-N., C. Proust, C. Perret, M.R., F.T., S.G., D.-A.T.).
Sorbonne Universités, University Pierre et Marie Curie, Université Paris 06, France; ICAN Institute of Cardiometabolism and Nutrition, Paris, France (A.-S.P.-N., C. Proust, C. Perret, M.R., F.T., S.G., D.-A.T.).
Stroke. 2018 Sep;49(9):2220-2223. doi: 10.1161/STROKEAHA.118.021101.
Background and Purpose- Arterial vasospasm is a well-known delayed complication of aneurysmal subarachnoid hemorrhage (aSAH). However, no validated biomarker exists to help clinicians discriminating patients with aSAH who will develop vasospasm (VSP) and identifying those who then deserve aggressive preventive therapy. We hypothesized that whole-blood miRNAs could be a source of candidate biomarkers for vasospasm. Methods- Using a next-generation sequencing approach, we performed whole-blood miRNA profiling between VSPpatients with aSAH and patients who did not develop vasospasm (VSP) in a prospective cohort of 32 patients. Profiling was performed on the admission day and 3 days before vasospasm. Results- Four hundred forty-two miRNAs were highly expressed in whole blood of patients with aSAH. Among them, hsa-miR-3177-3p demonstrated significant ( P=5.9×10; P=0.03) lower levels in VSP compared with VSP patients. Looking for whole-blood mRNA correlates of hsa-miR-3177-3p, we observed some evidence that the decrease in hsa-miR-3177-3p levels after aSAH was associated with an increase in LDHA mRNA levels in VSP ( P<10) but not in VSP ( P=0.66) patients. Conclusions- Whole-blood miRNA levels of hsa-miR-3177-3p could serve as a biomarker for vasospasm. Clinical Trial Registration- URL: https://www.clinicaltrials.gov . Unique identifier: NCT01779713.
背景与目的- 动脉血管痉挛是蛛网膜下腔出血（aSAH）的一种常见迟发性并发症。然而，目前尚无有效的生物标志物可以帮助临床医生区分哪些 aSAH 患者会发生血管痉挛（VSP），并确定哪些患者需要积极的预防治疗。我们假设全血 microRNA 可能是血管痉挛的候选生物标志物来源。方法- 我们采用下一代测序方法，对 32 例前瞻性队列研究中发生 VSP 的 aSAH 患者（VSP 组）和未发生血管痉挛的患者（非 VSP 组）的全血 microRNA 图谱进行了分析。分析在发病当天和血管痉挛前 3 天进行。结果- 在 aSAH 患者的全血中，有 442 种 microRNA 呈高表达。其中，hsa-miR-3177-3p 在 VSP 组中的表达水平显著低于 VSP 组（ P=5.9×10； P=0.03）。为了寻找 hsa-miR-3177-3p 的全血 mRNA 相关物，我们观察到一些证据表明，aSAH 后 hsa-miR-3177-3p 水平的降低与 VSP 患者（ P<10）而不是非 VSP 患者（ P=0.66）中 LDHA mRNA 水平的升高相关。结论- hsa-miR-3177-3p 的全血 microRNA 水平可作为血管痉挛的生物标志物。临床试验注册- URL：https://www.clinicaltrials.gov。唯一标识符：NCT01779713。
